24 HOUR DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. & Enc...
July 05 2018 - 7:00AM
Business Wire
A shareholder class action lawsuit has been filed against
Esperion Therapeutics, Inc. (NASDAQ: ESPR) (“Esperion” or the
“Company”) on behalf of investors who purchased the Company’s
common stock between February 22, 2017 and May 1, 2018,
inclusive (the “Class Period”).
FINAL DEADLINE NOTICE: Investors who purchased
Esperion’s common stock during the Class Period may, no later than July 6, 2018, seek to be appointed
as a lead plaintiff of the investor class.
Esperion investors are encouraged to contact Kaskela Law LLC
(David Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 –
1740 to discuss their important legal rights and options with
respect to this action prior to July 6, 2018. Investors may
also visit
http://kaskelalaw.com/case/esperion-therapeutics-inc/ to
submit their information to the firm online.
On May 2, 2018, Esperion announced results from its second
pivotal Phase 3 study for its cholesterol-lowering medication.
Esperion also disclosed that, although the trial met certain
primary endpoints, there were 13 deaths in the treatment group as
compared to only two in the control group. Following this news,
shares of the Company’s stock declined $24.75 per share, or over
35%, to close on May 2, 2018 at $45.75.
The shareholder class action lawsuit alleges, among other
things, that Esperion and certain of its senior executive officers
made false and misleading statements and/or failed to disclose to
investors that the Company’s cholesterol-lowering medication
entailed serious undisclosed safety risks, including death. The
complaint further alleges that, as a result of the foregoing,
investors purchased Esperion’s stock at artificially inflated
prices during the Class Period and suffered significant investment
losses following the Company’s May 2, 2018 disclosure.
Esperion investors are encouraged to contact Kaskela Law LLC at
(484) 258 – 1585 or (888) 715 – 1740, or via
http://kaskelalaw.com/case/esperion-therapeutics-inc/, to
discuss their legal rights and options prior to July 6,
2018. Kaskela Law LLC exclusively prosecutes shareholder
actions in state and federal courts throughout the country on
behalf of investors. For additional information about Kaskela Law
LLC please visit www.kaskelalaw.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180705005015/en/
KASKELA LAW LLCDavid Seamus Kaskela, Esq.201 King of
Prussia RoadSuite 650Radnor, PA
19087484-258-1585888-715-1740skaskela@kaskelalaw.comwww.kaskelalaw.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2024 to May 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2023 to May 2024